Related Experiment Video

Updated: Aug 15, 2026

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved

Roberto Valle1, Nadia Aspromonte, Mauro Feola

  • 1Heart Failure Unit, Department of Cardiology, Ospedale Civile, San Donà di Piave, Italy.

Journal of Cardiac Failure
|October 4, 2005
PubMed

Insights

Plasma B-type natriuretic peptide (BNP) levels effectively predict cardiovascular events in patients with heart failure and preserved ejection fraction. Higher BNP levels indicate a greater risk of death or hospital readmission within six months.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Biomarkers

Background:

  • Heart failure with preserved ejection fraction (HFpEF) affects half of all heart failure patients.
  • Neurohormonal activation is a key characteristic of HFpEF.
  • Plasma B-type natriuretic peptide (BNP) levels reflect left ventricular dysfunction severity.

Purpose of the Study:

  • To evaluate if plasma BNP levels can predict cardiovascular events in ambulatory HFpEF patients within six months.
  • To test the hypothesis that BNP measurement aids in risk stratification for HFpEF.

Main Methods:

  • 233 HFpEF patients (LVEF > 50%) were enrolled after acute HF stabilization.
  • Echocardiography assessed left ventricular systolic and diastolic function.
  • Plasma BNP levels were measured on admission; patients were followed for 6 months for combined cardiovascular death or HF readmission.

Main Results:

  • 48 composite endpoints (15 deaths, 33 readmissions) occurred among 233 patients.
  • Receiver operating curve analysis demonstrated BNP as a strong predictor (AUC = 0.84).
  • Multivariate Cox regression identified BNP cutoffs (200-500 pg/mL and ≥500 pg/mL) as significant predictors (HR=2.2, P<.04 and HR=5.8, P<.001, respectively).

Conclusions:

  • BNP levels are potent predictors of cardiovascular mortality and early readmission in patients with diastolic heart failure.
  • BNP measurements can guide follow-up intensity post-decompensation.
  • Elevated BNP levels correlate with a progressively worse prognosis in HFpEF.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...